Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014. “Since the second quarter, we have made tremendous progress in support of our pipeline and strategy,” said Lewis T. “Rusty” Williams, M.D., Ph.D., president and chief executive officer of Five Prime.
